Proposals for Next Classification Schema of Myeloid Neoplasms
Endowed Chair in Biochemistry and Molecular Biotechnology I
School of Public Health and Health Sciences
Dept of Biochem & Mol Biol And Dept of Chem
Health Informatics And Implementation Science
Cutler Chair in Vascular and Endovascular Surgery
The project aims to develop computational algorithms and software programs for analyzing high-throughput sequence data such as ChIP-Seq RNA-Seq small RNA sequencing data. PhD required. A strong background in computational biology especially experience with analyzing high-throughput sequencing data is highly desirable. Excellent communication and writing skills and the ability to work with experimental and computational collaborators are essential. To apply please forward CV cover letter and three references to: Zhiping.Weng@umassmed.edu
Please contact Dr. Weng for information on rotations that are available in her lab.
Donna M. and Robert J. Manning Chair in Neurosciences
Dr. Brown’s laboratory has focused on the identification of gene defects that elucidate the molecular pathogenesis of selected neuromuscular diseases including amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig’s disease), muscular dystrophy, adrenoleukodystrophy, hereditary neuropathy and hyperkalemic periodic paralysis.
Melvin S. and Sandra L. Cutler Chair in Biomedical Research
Dr. Henninger is a vascular neurologist with research interest in the neurobiology of axonal injury associated with traumatic brain injury and its contribution to functional outcome.
Imoigele P. Aisiku, MD’97 Chair in Health Equity and Diversity
<p >Rotation Projects <p >Rotation projects are designed to expose students to the molecular cell biology of solid tumors and to provide them with an appreciation for translational cancer research. Specific rotation projects, which are focused on the major themes of the lab, include: <p >Function and Regulation of Integrins (Cell Adhesion Receptors) in Cancer Epigenetic mechanisms that regulate integrin gene expression in human cancers Regulation of integrin expression and function during the EMT Role of specfic microRNAs (miRs) in regulating integrin function and signaling Contribution of integrins to carcinoma progression using mouse models of breast carcinoma <p >Vascular Endothelial Growth Factor (VEGF) Signaling, EMT and Carcinoma Progression Function and expression of VEGF receptors in carcinoma cells Regulation of VEGF transcription in response to EMT stimuli Role of miRs in regulating VEGF receptors and signaling Contribution of VEGF signaling to the behavior of aggressive, de-differentiated carcinomas <p >Nuclear Hormone Receptors and EMT Role of estrogen receptors in regulating the EMT Regulation of VEGF transcription by estrogen receptors
Joseph M. Streeter and Mary Streeter DeFeudis Chair in Surgery
Richard M. Haidack Professor in Medicine
Brian Silver MD, FRCPC, FAHA, FAAN, FANA
Dr. John Meyers Professor in Primary Care Medicine
Population and Quantitative Health Sciences
Biochemistry and Molecular Biotechnology
UMass Worcester Prevention Research Center
Healthcare Delivery and Population Sciences at UMass Chan - Baystate
Joseph D. Early Chair in Biomedical Research
Prevention Strategies for Second Primary Malignancies After CAR-T Therapy
The Darkest Side of AML: The TP53 Mutation
Clonal Hematopoiesis in Clinical Practice: Real-World Insights
Unpacking CHIP: Recent Updates, Remaining Questions
Dr Patel on the Impact of Donor-Engrafted Clonal Hematopoiesis on Outcomes With Auto-/Allo-HSCT
Effects of donor-engrafted clonal hematopoiesis in stem cell transplantation
High-Risk Myelodysplastic Syndrome Findings in the SELECT-MDS-1 Study
Stem Cell Transplantation: How Clonal Hematopoiesis Shapes Patient Outcomes
Olutasidenib as a Breakthrough for R/R mIDH1 AML Patients
The Impact of Mutations in Clonal Hematopoiesis
TP53 in MDS & AML Prognostication & Treatment Strategies
Exploring the Biological Basis of TP53-Aberrant MDS & AML
Improving Outcomes in Blast Phase Chronic Myeloid Leukemia
ASH Clinical News - Practical Solutions Amid Cuts to Federally Funded Research
OncLive with Dr. Patel and Dr. Gerber: p53 Immunohistochemistry
Early Identification of TP53-Mutant MDS and AML Using p53 Immunostaining
Point-of-Care p53 IHC Unveils TP53-Mutant MDS/AML
IHC Enables Rapid Identification of TP53-Mutant MDS/AML
ASH Clinical News: p53 Immunohistochemistry for TP53-Mutant MDS/AML
p53 Immunostain in TP53-Mutant MDS and AML